EponaCell was founded in 2010 as the first biotech company focusing on treating the musculoskeletal systems of animals using stem cells in the Czech Republic. It became certified for Good Manufacturing Practice and was given authorisation to manufacture cellular medicines. Aside from its own manufacturing activities, the company is also committed to research with the aim of constantly innovating current products and developing new ones.

During its time on the market, EponaCell has created a network of collaborating veterinary centres and strong links with leading veterinary orthopaedic surgeons as well as references of successfully treated horses and dogs and their satisfied owners.

EponaCell is based in Prague and is part of the business incubator Innovation Biomedical Centre at the Institute of Experimental Medicine, the Institute for Public Research. EponaCell uses its cellular products to treat patients in the Czech Republic as well as neighbouring countries with easy access in terms of logistics.

EponaCell is part of the biotech group SinBio focusing on advanced bio materials and cellular therapy for use in human and veterinary regenerative medicine.

We offer our services to patients from the following countries:



o eponacell 01

The company is strongly committed to researching new treatment methods and cellular products and for this reason acts as a supplier and partner to several major research and development products such as:


OPPI – Collaboration - Klastry

“Nanoprogres” with registration number 5.1 SPK 02/018
“Nanoprogres II” with registration number 5.1. SPK 02/050


Resarch of nanofibrous scaffolds blended with hydroxyapatite and testing their osteogenic potential on horse extraembryonic mesenchymal stem cells (EMSC). Development methods of treatment skin defects in mammals using composite nanofibers scaffolds containing allogeneic extraembryonic stem cells.


Low temperature plasma in medicine. TAČR- Alfa; TA04010449; 2014-2017

Innovation vouchers

Developing procedures for handling stem cells and testing two and three-dimensional media for potential use in clinical applications focusing on developing replacement parenchymal organs; 2013-2014